ARTham Therapeutics has initiated a phase-I clinical trial on PI3K inhibitor ART-001
ARTham Therapeutics has reached an important milestone within our clinical stage portfolio. As planned, we are pleased to announce initiation of phase-I clinical trial for PI3K inhibitor ART-001 in Japan. This is a randomized, placebo-controlled, double-blind, single-center study to evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of ART-001 in Japanese healthy volunteers.
For more information about the study, please visit the following website:
Post successful Ph1, ART-001 will enter Ph2 (hPOC) studies for vascular malformations, with focus on treating pediatric rare indications that address significant unmet medical need. At ARTham Therapeutics our mission is to deliver “Medicines that matter” to patients and this milestone exemplifies that commitment.
Contact information: firstname.lastname@example.org